BAM
MRVI icon

Belpointe Asset Management’s Maravai LifeSciences MRVI Stock Holding History

Belpointe Asset Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-313
Closed -$4.38K – 2280
2023
Q1 		$4.38K Buy
+313
New +$4.5K ﹤0.01% 3063

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Belpointe Asset Management's MRVI Position: Q2 2023 in Review

Belpointe Asset Management sold out of Maravai LifeSciences (MRVI) in Q2 2023, closing a stake of 313 shares — an estimated $4.38K sold.

Belpointe Asset Management first reported a position in MRVI in Q1 2023 and held it in 1 quarter. The position peaked at $4.38K in Q1 2023. 221 funds tracked by Wall St. Rank hold MRVI as of Q2 2023.

  • Belpointe Asset Management reported no remaining Maravai LifeSciences position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 313 Maravai LifeSciences shares in Q2 2023, an estimated $4.38K.
  • Belpointe Asset Management first reported a position in Maravai LifeSciences in Q1 2023 and held it in 1 quarter.
  • Belpointe Asset Management's Maravai LifeSciences position peaked at $4.38K in Q1 2023.
  • 221 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.